Rapid Dose Therapeutics Corp. (DOSE.CN)
Rapid Dose Therapeutics Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Burlington, ON, CA. The stock last traded at $0.10, up 5.00% on the session, giving a market capitalisation of $14.2M. Its beta of -0.91 implies it has historically moved less than the broad market.
Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagship product is QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter medicines—directly into the bloodstream. They offer specific QuickStrip variants like QuickStrip energy for caffeine delivery, QuickStrip B12 for vitamin B12 supplementation, and QuickStrip sleep for melatonin. Beyond its proprietary products, the firm also delivers comprehensive services encompassing product innovation, manufacturing, and consultation to industries including nutraceuticals, cannabis healthcare, and pharmaceutical production. Rapid Dose Therapeutics maintains a significant research collaboration with McMaster University, focusing on crafting enhanced biopolymer compositions for oral dissolvable thin films and investigating an orally administered vaccine candidate for COVID-19.
Rapid Dose Therapeutics Corp. is most often compared with the following Healthcare names: